Get the Stockscreener App
0.0111
0.00%
0.00
Trevena Inc stock is traded at $0.0111, with a volume of 0.
It is up +0.00% in the last 24 hours and up +0.00% over the past month.
See More
Previous Close:
$0.0111
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$N/A
Revenue:
$547.00K
Net Income/Loss:
$-34.02M
P/E Ratio:
-0.000237
EPS:
-46.9127
Net Cash Flow:
$-27.11M
1W Performance:
+0.00%
1M Performance:
+0.00%
6M Performance:
-7.50%
1Y Performance:
+221.67%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$1.15
Trevena Inc Stock (TRVN) Company Profile
Compare TRVN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRVN
Trevena Inc
|
0.00 | 0 | 547.00K | -34.02M | -27.11M | -46.91 |
VRTX
Vertex Pharmaceuticals Inc
|
424.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
717.83 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
809.79 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.06 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
314.83 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Trevena Inc Stock (TRVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-15-21 | Initiated | Oppenheimer | Perform |
| Sep-14-20 | Initiated | Guggenheim | Buy |
| Aug-28-20 | Initiated | Cantor Fitzgerald | Overweight |
| May-31-19 | Resumed | H.C. Wainwright | Buy |
| Nov-05-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-12-18 | Downgrade | Needham | Buy → Hold |
| Oct-10-18 | Downgrade | Jefferies | Buy → Hold |
| Nov-08-17 | Reiterated | Needham | Buy |
| Oct-16-17 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-12-17 | Reiterated | H.C. Wainwright | Buy |
| May-08-17 | Reiterated | Needham | Buy |
| Feb-23-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-22-17 | Reiterated | FBR & Co. | Outperform |
| Feb-02-17 | Initiated | Ladenburg Thalmann | Buy |
| Jan-09-17 | Initiated | H.C. Wainwright | Buy |
| Jan-05-17 | Initiated | Oppenheimer | Outperform |
| May-17-16 | Reiterated | FBR Capital | Outperform |
| May-17-16 | Reiterated | Needham | Buy |
| Mar-29-16 | Initiated | FBR Capital | Outperform |
| Sep-01-15 | Reiterated | Wedbush | Outperform |
| Aug-03-15 | Initiated | Brean Capital | Buy |
View All
Trevena Inc Stock (TRVN) Latest News
Health News Round upopioid pain drugs, Ebola vaccinations in Uganda and much mmore - Devdiscourse
Diabetic Neuropathy Pipeline Set for Significant - openPR.com
Diabetic Neuropathy Pipeline Set for Significant Breakthroughs by 2026 with 20+ Therapies and Robust Clinical Advancements | DelveInsight - Barchart
Polaris Venture Partners V L P Net WorthInsider Trades and Bio as of Apr 22, 2026 - Benzinga
Verastem, Inc. (VSTM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Chronic and Acute Pain Treatment Pipeline Shows Strong Momentum as 180+ Pharma Companies in the Race | DelveInsight - Barchart.com
TherapeuticsMD, Inc. (TXMD) stock price, news, quote and history - Yahoo Finance UK
Trevena (STU:6T4) PB Ratio : (As of Mar. 28, 2026) - gurufocus.com
Europe Stocks: Research Stocks from Europe Stock Market - GuruFocus
Stock List: Research Stocks from Around the World - GuruFocus
SMX (Security Matters) Public Limited CompanyOrdinary Shares (NQ: SMX - The Chronicle-Journal
Wall Street closes lower, as war on Iran fuels inflation worries - marketscreener.com
S&P Closes Out Third Straight Week of Loses | Closing Bell - marketscreener.com
US Stocks Brief: S&P Futures Down 0.25% - marketscreener.com
Elon Musk's SpaceX weighs Nasdaq listing, sources say - marketscreener.com
Celebrity-studded Caliwater bets cactus is next big wave in hydration - Food Dive
Wall Street opens lower as investors weigh Middle East war risks - marketscreener.com
TRVN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Trump Says Stock Market Hit 53 New Highs on His Watch - marketscreener.com
US software stocks climb as Anthropic announcement sparks relief rally - marketscreener.com
VINC Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
U.S. S&P 500 E-mini and Nasdaq 100 futures flat, Dow futures down 0.1% - marketscreener.com
Wall Street ends higher, lifted by Nvidia and other AI stocks - marketscreener.com
Tg-17 Inc changes corporate name to Our Bond, Inc. - marketscreener.com
Coinshares Updates on Fourth Quarter, Plans $0.33 Dividend Per Share - marketscreener.com
Investor Increases its Stake in Nasdaq - marketscreener.com
Why Arcadium Lithium Shares Are Trading Higher By 28%; Here Are 20 Stocks Moving Premarket - Intellectia AI
Novakand Pharma applies for Nasdaq's approval of continued listing - marketscreener.com
S&P 500, Nasdaq turn negative; S&P down 0.4%, Nasdaq falls 0.9% - marketscreener.com
Braiin Shares to Begin Trading on Nasdaq - marketscreener.com
Columbus Circle Capital Corp II Prices $200 Million Initial Public Offering - marketscreener.com
Sanofi Concludes $2.2 Billion Takeover of Dynavax Technologies - marketscreener.com
Spring Valley Acquisition Corp. IV Prices $200 Million IPO - marketscreener.com
Unique Global Innovative Solutions Corp. (Ugiz) announces intent to pursue Nasdaq uplisting and capital raise - marketscreener.com
Generate Biomedicines Inc announces initial public offering - marketscreener.com
RCI Hospitality Receives Non-Compliance Letter from Nasdaq - marketscreener.com
Earnings Flash (NDAQ) Nasdaq Posts Q4 Revenue $2.80B - marketscreener.com
Chronic and Acute Pain Clinical Trial Pipeline Analysis: - GlobeNewswire
North American Morning Briefing : Nasdaq Futures Rise; Trade Relations, Earnings in Focus -2 - marketscreener.com
Trevena (NASDAQ:TRVN) Share Price Passes Above Fifty Day Moving Average – Should You Sell? - Defense World
Diabetic Neuropathy Clinical Trial Pipeline Gains Momentum: 18+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - The Manila Times
Diabetic Neuropathy Clinical Trial Pipeline Gains Momentum: - GlobeNewswire
What technical patterns form on Trevena Inc. (6T4) stock chartsJuly 2025 Market Mood & Fast Entry and Exit Trade Plans - bollywoodhelpline.com
Trevena Restructures China Royalty Rights to Exit Debt - The Globe and Mail
Critical Contrast: Ampio Pharmaceuticals (NYSE:AMPE) vs. Trevena (NASDAQ:TRVN) - Defense World
Trevena Signs Assignment and Release Agreement With R-Bridge Investment Four and Jiangsu Nhwa Pharmaceutical - TradingView — Track All Markets
Trevena (NASDAQ:TRVN) Shares Cross Below Fifty Day Moving Average – Here’s What Happened - Defense World
Ray Therapeutics Appoints Scott Braunstein, M.D., as Chairman of the Board of Directors - BioSpace
How Trevena Inc. (6T4) stock valuation compares with sectorQuarterly Portfolio Review & Risk Managed Investment Entry Signals - ulpravda.ru
Analyst Upgrade: How Trevena Inc. (6T4) stock benefits from digital adoptionJuly 2025 Action & Long Hold Capital Preservation Tips - ulpravda.ru
Published on: 2026-01-09 03:04:06 - ulpravda.ru
Trevena Inc Stock (TRVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.78%
3.01%
Cap:
|
Volume (24h):